532482 Share Price Performance
₹0
-453.15 (-100.00%)
Price ₹0
Fair Value₹698.29
Share Pricen/a
Narrative Update • May 01
Granules India Limited Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
532482 Community Narratives
AN
Fair Value
·Fair Value ₹698.29 6.5% overvalued intrinsic discount
FDA Remediation And Genome Valley Ramp-Up Will Unlock Capacity
0users have liked this narrative
1users have commented on this narrative
20users have followed this narrative
AN
Fair Value
·Fair Value ₹799.28 7.0% undervalued intrinsic discount
Expanding API Capacity And Aging Global Population Will Fuel Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value ₹588 26.4% overvalued intrinsic discount
Peptide CDMO Overcapacity And Debt Will Undermine Performance
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
FDA Remediation And Genome Valley Ramp-Up Will Unlock Capacity
Key Takeaways Expansion into peptide therapeutics and CDMO segments enhances diversification and margin potential in high-growth global markets. Increased manufacturing capacity, regulatory filings, and strategic focus on exports strengthen revenue visibility and long-term operational resilience.Read more
AN
₹698.29
6.5% overvalued intrinsic discount
Fair Value
Revenue
15.14% p.a.
Profit Margin
14.66%
Future PE
21.19x
Price in 2029
₹993.66
Expanding API Capacity And Aging Global Population Will Fuel Opportunity
Key Takeaways Aggressive expansion into high-value generics, oncology, peptides, and CDMO positions Granules India for sustained revenue and margin growth beyond market forecasts. Strong ESG credentials, vertically integrated manufacturing, and strategic acquisitions enable the company to capture global demand and secure premium long-term contracts.Read more
AN
₹799.28
7.0% undervalued intrinsic discount
Fair Value
Revenue
19.11% p.a.
Profit Margin
14.86%
Future PE
21.61x
Price in 2029
₹1.14k
Peptide CDMO Overcapacity And Debt Will Undermine Performance
Key Takeaways Expansion into CDMO and new therapeutics is straining profitability due to overcapacity, competition, and high capital needs amid long gestation periods. Overreliance on key generics, increasing regulatory costs, and export headwinds may weaken growth, suppress margins, and heighten financial risks.Read more
AN
₹588
26.4% overvalued intrinsic discount
Fair Value
Revenue
13.84% p.a.
Profit Margin
13.44%
Future PE
20.14x
Price in 2029
₹836.72
Trending Discussion
Recently Updated Narratives
AN
532482: Fair Outlook Will Depend On Upcoming Results And Dividend Decision
Fair Value: ₹698.29 6.5% overvalued intrinsic discount
20 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
532482: Higher Fair Value Will Rely On Sustained Margin Improvement
Fair Value: ₹799.28 7.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
532482: Preferential Fundraising And Warrants Will Shape A Steady Outlook
Fair Value: ₹588 26.4% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Flawless balance sheet with reasonable growth potential and pays a dividend.
0 Risks
2 Rewards
Granules India Limited Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 24.01
- 65.17%
- 11.05%
- 26.3%
About 532482
- Founded
- 1984
- Employees
- 4066
- CEO
- WebsiteView website
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
